A miRNA-PEPTIDE FUSION AS A VACCINE CANDIDATE AGAINST THE NOVEL CORONAVIRUS (COVID-19). EXOSOMES AS POTENTIAL BIOMARKERS OF SARS-COV-2 IN LUNG: AFTER AND BEFORE VACCINATION LCR_2020_B008-13

A new coronavirus named Covid-19 was reported in Wuhan, China in December 2019. The first time these cases were published they were classified as “pneumonia of unknown etiology”. The etiology of this illness is now attributed to a novel virus belonging to the coronavirus (CoV) family, COVID-19. Different from both MERS-CoV and SARS-CoV, 2019-nCoV it is the seventh member of the family of coronaviruses to infect humans. We have designed a preventive vaccine in Silico aimed to protect against Covid-19 infection and transmission. Our analysis identified 16 microRNA (miRNA) with theorical Exosome Affinity (EA) with peptide among 85.44-92.84 range. According to antiviral monitoring after and before vaccination using the candidate miRNA-peptide number 13 (LCR_2020_B008-13) with value EA=92.84 Ro. We proposed the exosomes as biomarkers of SARS-Covid-2 in lung: after and before vaccination. Due to, the miRNA-peptides, in Silico, manifesting highly affinity with exosomes, where our chimera LCR_2020_B008-13 could reach a representative activity against the Covid-19 virogenes due to “exosome sequestering”; and also, the treatment of cancer diseases due to “podosome depletion” in metastasis stage.